Dr. Helfand on how genomic testing provides real-time status of prostate tumor

July 29, 2021

Urology Times staff

Video

Around the Practice

Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, discusses how genomic testing is a great tool for identifying “what is going on in the tumor ‘right now.’”

Related Videos

Expert on prostate cancer

Expert on prostate cancer

Expert on prostate cancer

Experts on prostate cancer

Around the Practice July 21, 2021: Bladder Cancer Cases

Genetic, Genomic Testing in Heavily Treated, Metastatic Castrate-Resistant Prostate Cancer

Genetic, Genomic Testing in Newly Diagnosed, High-Grade, High-Risk Prostate Cancer

Related Content

Around the Practice: The Management of Biochemical Recurrence in Prostate Cancer

Around the Practice: The Management of Biochemical Recurrence in Prostate Cancer

Around the Practice: The Management of Biochemical Recurrence in Prostate Cancer

Related Content

Around the Practice: The Management of Biochemical Recurrence in Prostate Cancer

Around the Practice: The Management of Biochemical Recurrence in Prostate Cancer

This article reviews new imaging technologies that may improve early detection of biochemical recurrence after definitive treatment for prostate cancer. This article also features insights from oncology experts Raoul Concepcion, MD; Judd Moul, MD; Brian Helfand, MD; Munir Ghesani, MD.

Terms and Conditions

Do not sell my Personnal Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.